Business News • PR NewsWire • University of California Irvine (UCI) Doses First Patient in Phase IIa Clinical Trial Using Stemedica's Stem Cells for Alzheimer's disease

University of California Irvine (UCI) Doses First Patient in Phase IIa Clinical Trial Using Stemedica's Stem Cells for Alzheimer's disease

University of California Irvine (UCI) Doses First Patient in Phase IIa Clinical Trial Using Stemedica's Stem Cells for Alzheimer's disease

IRVINE, Calif., Nov. 1, 2016 /PRNewswire/ -- Stemedica International, SA, a Stemedica Cell Technologies Inc. subsidiary that uses its proprietary allogeneic stem-cell therapies for Alzheimer's disease, announces enrollment of its first patient at the University of California, Irvine...

View More : http://www.prnewswire.com/news-releases/university-of-california-irvine-uci-doses-first-patient-in-phase-iia-clinical-tr...

Releted News by prnewswire

Oddup Extends Startup Reach to South East Asia - Manila, Philippines

Daqo New Energy to Announce Unaudited Third Quarter 2016 Results on November 15, 2016